Collaborations

XOMA has successfully completed collaborations with multiple biotechnology and pharmaceutical companies for various disease areas. Today, we work with collaborators on their disease areas of interest, coordinating with them to develop potent monoclonal antibodies to their targets.

Novartis

XOMA and Novartis had a worldwide, multi-product, cost and profit sharing collaborative agreement for the development and commercialization of antibody products for the treatment of cancer. This agreement was initially between XOMA and Chiron, but transferred to Novartis in April 2006, upon the acquisition of Chiron by Novartis. The lead product candidate in this collaboration is HCD122, a fully human, antagonistic antibody that targets the CD40 antigen and is in phase I clinical trials.

Schering-Plough

XOMA is conducting monoclonal antibody discovery and development projects against undisclosed targets for Schering-Plough and Takeda.  The collaboration involves multiple discovery programs.

Takeda

Since 2006, we have had a fully funded collaboration with Takeda for therapeutic antibody discovery and development.  Through this collaboration, we discover and optimize therapeutic antibodies against targets selected by Takeda. In 2009, we signed a $29 million expanded collaboration agreement for additional discovery and development programs.